Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “buy” rating restated by research analysts at Chardan Capital in a research note issued to investors on Thursday. They currently have a $18.50 target price on the biopharmaceutical company’s stock, up from their prior target price of $16.50. Chardan Capital’s price target would indicate a potential upside of 22.76% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. BidaskClub upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 19th. Robert W. Baird restated an “outperform” rating and set a $12.00 price target on shares of Amicus Therapeutics in a report on Friday, June 30th. ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 9th. Finally, Leerink Swann restated an “outperform” rating and set a $17.00 price target (down from $18.00) on shares of Amicus Therapeutics in a report on Saturday, September 16th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Amicus Therapeutics currently has an average rating of “Buy” and a consensus price target of $18.07.

Shares of Amicus Therapeutics (FOLD) opened at 15.06 on Thursday. The firm’s market capitalization is $2.48 billion. Amicus Therapeutics has a one year low of $4.41 and a one year high of $16.60. The firm’s 50-day moving average is $14.11 and its 200 day moving average is $10.59.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. The firm had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. During the same period in the prior year, the business earned ($0.40) EPS. Equities research analysts predict that Amicus Therapeutics will post ($1.32) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Amicus Therapeutics, Inc. (FOLD) Rating Reiterated by Chardan Capital” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/amicus-therapeutics-inc-fold-rating-reiterated-by-chardan-capital/1615070.html.

In other news, major shareholder Life Sciences Maste Perceptive bought 1,500,000 shares of the stock in a transaction dated Thursday, July 13th. The shares were bought at an average cost of $12.25 per share, with a total value of $18,375,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.40% of the stock is owned by corporate insiders.

Several large investors have recently modified their holdings of FOLD. Janus Henderson Group PLC acquired a new position in shares of Amicus Therapeutics during the second quarter worth approximately $70,762,000. Wellington Management Group LLP raised its position in shares of Amicus Therapeutics by 358.4% during the first quarter. Wellington Management Group LLP now owns 5,341,132 shares of the biopharmaceutical company’s stock worth $38,083,000 after purchasing an additional 4,175,995 shares during the period. Morgan Stanley raised its position in shares of Amicus Therapeutics by 99.4% during the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock worth $43,696,000 after purchasing an additional 3,055,039 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Amicus Therapeutics during the first quarter worth approximately $21,394,000. Finally, Farallon Capital Management LLC acquired a new position in shares of Amicus Therapeutics during the second quarter worth approximately $30,210,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.